Using an ultra-sensitive and high-throughput isolation technology, researchers were able to characterize and identify the neoantigens driving the antitumor responses in a patient.
Using an ultra-sensitive and high-throughput isolation technology, researchers were able to characterize and identify the neoantigens driving the antitumor responses in a patient.